{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:15Z","timestamp":1750636815340},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,2]]},"DOI":"10.7759\/cureus.46391","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:36:27Z","timestamp":1696314987000},"source":"Crossref","is-referenced-by-count":1,"title":["Do Tofacitinib Generics Exhibit Conventional Synthetic Disease-Modifying Anti-rheumatic Drug and Non-steroidal Anti-inflammatory Drug-Sparing Ability in the Management of Axial Spondyloarthritis?"],"prefix":"10.7759","author":[{"given":"Arvind","family":"Ganapati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suvrat","family":"Arya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod","family":"Chebbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy","family":"Doley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin R","family":"Jeevanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh K","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221035","article-title":"Axial spondyloarthritis","volume":"80","author":"Navarro-Comp\u00e1n V","year":"2021","unstructured":"Navarro-Comp\u00e1n V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021, 80:1511-21. 10.1136\/annrheumdis-2021-221035","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24025","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward MM","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al.. 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2019, 71:1285-99. 10.1002\/acr.24025","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde D","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, et al.. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet. 2019, 394:2108-17. 10.1016\/S0140-6736(19)32534-6","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar A","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, et al.. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022, 400:369-79. 10.1016\/S0140-6736(22)01212-0","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde D","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, et al.. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017, 76:1340-7. 10.1136\/annrheumdis-2016-210322","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar A","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, et al.. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021, 80:1004-13. 10.1136\/annrheumdis-2020-219601","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde D","year":"2018","unstructured":"van der Heijde D, Baraliakos X, Gensler LS, et al.. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018, 392:2378-87. 10.1016\/S0140-6736(18)32463-2","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key070","article-title":"The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis","volume":"58","author":"Veale DJ","year":"2019","unstructured":"Veale DJ, McGonagle D, McInnes IB, et al.. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford). 2019, 58:197-205. 10.1093\/rheumatology\/key070","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030270","article-title":"The use of Janus kinase inhibitors in axial spondyloarthritis: current insights","volume":"15","author":"Toussirot E","year":"2022","unstructured":"Toussirot E. The use of Janus kinase inhibitors in axial spondyloarthritis: current insights. Pharmaceuticals (Basel). 2022, 15:270. 10.3390\/ph15030270","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref10","unstructured":"New treatment approved for ankylosing spondylitis. FDA OKs first JAK inhibitor, tofacitinib. (2021). Accessed: May 15, 2023: https:\/\/spondylitis.org\/research-new\/new-treatment-approved-for-ankylosing-spondylitis-fda-oks-first-jak-inhibitor\/."},{"key":"ref11","unstructured":"Pfizer\u2019s XELJANZ\u00ae (tofacitinib) receives marketing authorization in the European Union for the treatment of active ankylosing spondylitis. (2021). Accessed. May 15, 2023: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-xeljanzr-tofacitinib-receives-marketing."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro S","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al.. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023, 82:19-34. 10.1136\/ard-2022-223296","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002253","article-title":"Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Navarro-Comp\u00e1n V","year":"2022","unstructured":"Navarro-Comp\u00e1n V, Wei JC, Van den Bosch F, et al.. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open. 2022, 8:e002253. 10.1136\/rmdopen-2022-002253","journal-title":"RMD Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key104","article-title":"Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients","volume":"57","author":"Maksymowych WP","year":"2018","unstructured":"Maksymowych WP, van der Heijde D, Baraliakos X, et al.. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology (Oxford). 2018, 57:1390-9. 10.1093\/rheumatology\/key104","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14570","article-title":"Effectiveness and safety of generic tofacitinib in spondyloarthritis: a real-world retrospective analysis from India","volume":"26","author":"Phatak S","year":"2023","unstructured":"Phatak S, Khenat A, Malandkar M, Amin S. Effectiveness and safety of generic tofacitinib in spondyloarthritis: a real-world retrospective analysis from India. Int J Rheum Dis. 2023, 26:487-92. 10.1111\/1756-185X.14570","journal-title":"Int J Rheum Dis"},{"key":"ref16","article-title":"Low dose methotrexate in seronegative spondyloarthro pathy: result of a double blind, placebo controlled trial","volume":"12","author":"Upadhyaya S","year":"2004","unstructured":"Upadhyaya S, Aggarwal A, Misra R. Low dose methotrexate in seronegative spondyloarthro pathy: result of a double blind, placebo controlled trial. J Indian Rheumatol Assoc. 2004, 12:6-10.","journal-title":"J Indian Rheumatol Assoc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05433-5","article-title":"Combination of methotrexate and sulfasalazine is an efficacious option for axial spondyloarthritis in a resource-limited, real-world clinical setting: a prospective cohort study","volume":"40","author":"Ganapati A","year":"2021","unstructured":"Ganapati A, Gowri M, Antonisamy B, Danda D. Combination of methotrexate and sulfasalazine is an efficacious option for axial spondyloarthritis in a resource-limited, real-world clinical setting: a prospective cohort study. Clin Rheumatol. 2021, 40:1871-9. 10.1007\/s10067-020-05433-5","journal-title":"Clin Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13124","article-title":"A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis","volume":"21","author":"Khanna Sharma S","year":"2018","unstructured":"Khanna Sharma S, Kadiyala V, Naidu G, Dhir V. A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. Int J Rheum Dis. 2018, 21:308-14. 10.1111\/1756-185X.13124","journal-title":"Int J Rheum Dis"},{"key":"ref19","article-title":"A prospective double blind placebo controlled trial of combination disease modifying antirheumatic drugs vs. monotherapy (sulfasalazine) in patients with inflammatory low backache in ankylosing spondylitis and undifferentiated spondyloarthropathy","volume":"S1","author":"Venkatesh S","year":"2015","unstructured":"Venkatesh S, Viswanath VV, Tripathi D, Ansari M, Agarwal V. A prospective double blind placebo controlled trial of combination disease modifying antirheumatic drugs vs. monotherapy (sulfasalazine) in patients with inflammatory low backache in ankylosing spondylitis and undifferentiated spondyloarthropathy. J Arthritis. 2015, S1:001.","journal-title":"J Arthritis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit M","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, et al.. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009, 68:777-83. 10.1136\/ard.2009.108233","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado P","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011, 70:47-53. 10.1136\/ard.2010.138594","journal-title":"Ann Rheum Dis"},{"key":"ref22","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994, 21:2286-91.","journal-title":"J Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.1.66","article-title":"The Bath Ankylosing Spondylitis Patient Global Score (BAS-G)","volume":"35","author":"Jones SD","year":"1996","unstructured":"Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol. 1996, 35:66-71. 10.1093\/rheumatology\/35.1.66","journal-title":"Br J Rheumatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen SB","year":"2020","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al.. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020, 6:e001395. 10.1136\/rmdopen-2020-001395","journal-title":"RMD Open"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05270-6","article-title":"Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies","volume":"43","author":"Gialouri CG","year":"2023","unstructured":"Gialouri CG, Moustafa S, Thomas K, Hadziyannis E, Vassilopoulos D. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int. 2023, 43:421-35. 10.1007\/s00296-022-05270-6","journal-title":"Rheumatol Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/189634-do-tofacitinib-generics-exhibit-conventional-synthetic-disease-modifying-anti-rheumatic-drug-and-non-steroidal-anti-inflammatory-drug-sparing-ability-in-the-management-of-axial-spondyloarthritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:53Z","timestamp":1707508193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/189634-do-tofacitinib-generics-exhibit-conventional-synthetic-disease-modifying-anti-rheumatic-drug-and-non-steroidal-anti-inflammatory-drug-sparing-ability-in-the-management-of-axial-spondyloarthritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.46391","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,2]]}}}